Acrux Limited (ARUXF)
USD 0.03
(0.0%)
USD 0.03
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 | 8.96 Million AUD | -32.53% |
| 2023 | 13.28 Million AUD | -7.11% |
| 2022 | 14.3 Million AUD | -38.69% |
| 2021 | 23.32 Million AUD | 30.79% |
| 2020 | 17.83 Million AUD | -27.0% |
| 2019 | 24.43 Million AUD | -24.8% |
| 2018 | 32.49 Million AUD | -31.32% |
| 2017 | 47.3 Million AUD | -11.36% |
| 2016 | 53.37 Million AUD | 10.05% |
| 2015 | 48.49 Million AUD | -8.88% |
| 2014 | 53.22 Million AUD | 0.62% |
| 2013 | 52.89 Million AUD | -9.58% |
| 2012 | 58.49 Million AUD | -0.84% |
| 2011 | 58.99 Million AUD | -29.44% |
| 2010 | 83.6 Million AUD | 139.21% |
| 2009 | 34.95 Million AUD | -15.31% |
| 2008 | 41.26 Million AUD | 102.6% |
| 2007 | 20.36 Million AUD | -12.33% |
| 2006 | 23.23 Million AUD | -25.28% |
| 2005 | 31.09 Million AUD | 218.66% |
| 2004 | 9.75 Million AUD | -24.04% |
| 2003 | 12.84 Million AUD | -30.02% |
| 2002 | 18.35 Million AUD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 FY | 9.95 Million AUD | -25.07% |
| 2024 Q2 | 12.01 Million AUD | -9.55% |
| 2024 Q4 | 8.96 Million AUD | -25.41% |
| 2023 Q2 | 10.36 Million AUD | -27.53% |
| 2023 Q4 | 13.28 Million AUD | 28.17% |
| 2023 FY | 13.28 Million AUD | -7.11% |
| 2022 FY | 14.3 Million AUD | -38.69% |
| 2022 Q2 | 17.16 Million AUD | -26.43% |
| 2022 Q4 | 14.3 Million AUD | -16.66% |
| 2021 Q2 | 17.62 Million AUD | -1.21% |
| 2021 FY | 23.32 Million AUD | 30.79% |
| 2021 Q4 | 23.32 Million AUD | 32.39% |
| 2020 Q2 | 20.08 Million AUD | -17.81% |
| 2020 Q4 | 17.83 Million AUD | -11.18% |
| 2020 FY | 17.83 Million AUD | -27.0% |
| 2019 Q2 | 28.47 Million AUD | -12.36% |
| 2019 Q4 | 24.43 Million AUD | -14.19% |
| 2019 FY | 24.43 Million AUD | -24.8% |
| 2018 Q2 | 37.16 Million AUD | -21.45% |
| 2018 FY | 32.49 Million AUD | -31.32% |
| 2018 Q4 | 32.49 Million AUD | -12.57% |
| 2017 Q4 | 47.3 Million AUD | -19.08% |
| 2017 FY | 47.3 Million AUD | -11.36% |
| 2017 Q2 | 58.45 Million AUD | 9.53% |
| 2016 Q4 | 53.37 Million AUD | 7.38% |
| 2016 FY | 53.37 Million AUD | 10.05% |
| 2016 Q2 | 49.7 Million AUD | 2.5% |
| 2015 Q4 | 48.49 Million AUD | 7.43% |
| 2015 FY | 48.49 Million AUD | -8.88% |
| 2015 Q2 | 45.14 Million AUD | -15.18% |
| 2014 Q2 | 76.69 Million AUD | 45.0% |
| 2014 FY | 53.22 Million AUD | 0.62% |
| 2014 Q4 | 53.22 Million AUD | -30.61% |
| 2013 Q2 | 46.36 Million AUD | -20.74% |
| 2013 FY | 52.89 Million AUD | -9.58% |
| 2013 Q4 | 52.89 Million AUD | 14.07% |
| 2012 FY | 58.49 Million AUD | -0.84% |
| 2012 Q4 | 58.49 Million AUD | 0.0% |
| 2011 FY | 58.99 Million AUD | -29.44% |
| 2011 Q4 | 58.99 Million AUD | 0.0% |
| 2010 Q4 | 83.6 Million AUD | 0.0% |
| 2010 FY | 83.6 Million AUD | 139.21% |
| 2009 Q4 | 34.95 Million AUD | 0.0% |
| 2009 FY | 34.95 Million AUD | -15.31% |
| 2008 Q4 | 41.26 Million AUD | 0.0% |
| 2008 FY | 41.26 Million AUD | 102.6% |
| 2007 FY | 20.36 Million AUD | -12.33% |
| 2007 Q4 | 20.36 Million AUD | 0.0% |
| 2006 FY | 23.23 Million AUD | -25.28% |
| 2006 Q4 | 23.23 Million AUD | 0.0% |
| 2005 Q4 | 31.09 Million AUD | 0.0% |
| 2005 FY | 31.09 Million AUD | 218.66% |
| 2004 FY | 9.75 Million AUD | -24.04% |
| 2004 Q4 | 9.75 Million AUD | 0.0% |
| 2003 FY | 12.84 Million AUD | -30.02% |
| 2002 FY | 18.35 Million AUD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 76.927% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | -24.145% |
| SQZ Biotechnologies Company | 107.18 Million USD | 91.638% |
| Evofem Biosciences, Inc. | 10.55 Million USD | 15.075% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 93.117% |
| Mesoblast Limited | 667.9 Million USD | 98.658% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -12285.822% |
| Genus plc | 1.02 Billion USD | 99.129% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | -559.843% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -1696.052% |
| Marizyme, Inc. | 22.01 Million USD | 59.287% |
| ContraFect Corporation | 20.67 Million USD | 56.657% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -1329.506% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -2196.05% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -2245.248% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | -525.894% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | -116.183% |
| MultiCell Technologies, Inc. | 126.22 USD | -7100993.329% |
| Accustem Sciences Inc. | 939.68 Thousand USD | -853.826% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 93.025% |
| EV Biologics, Inc. | 431.71 Thousand USD | -1976.143% |
| Q BioMed Inc. | 3.51 Million USD | -154.955% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 74.522% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -1063.053% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -3330.459% |
| Biomind Labs Inc. | 73.81 Thousand USD | -12041.86% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 462.85 Million USD | 98.064% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | 70.138% |
| Skye Bioscience, Inc. | 11.94 Million USD | 24.936% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | -170.539% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | -226.362% |
| Arch Therapeutics, Inc. | 1.95 Million USD | -357.719% |
| IMV Inc. | 31.33 Million USD | 71.395% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -1203.736% |
| Curative Biotechnology, Inc. | 2.6 Million USD | -244.308% |
| GB Sciences, Inc. | 103.44 Thousand USD | -8564.759% |
| Alpha Cognition Inc. | 2.45 Million USD | -265.513% |
| HST Global, Inc. | 1526.00 USD | -587252.556% |
| CSL Limited | 38.02 Billion USD | 99.976% |
| Halberd Corporation | 10.13 Thousand USD | -88371.03% |
| Enzolytics Inc. | 361.7 Million USD | 97.522% |
| Resverlogix Corp. | 8.11 Million USD | -10.45% |
| Affymax, Inc. | 7.44 Million USD | -20.422% |
| SYBLEU INC | 330.46 Thousand USD | -2612.214% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | -377.294% |
| argenx SE | 4.54 Billion USD | 99.803% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | 67.925% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 81.21% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -39244.19% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | -0.155% |
| AVAX Technologies, Inc. | 7.37 Million USD | -21.497% |
| Zenith Capital Corp. | 7410.00 USD | -120858.165% |
| Genscript Biotech Corporation | 3.38 Billion USD | 99.735% |
| Ember Therapeutics, Inc. | 184.00 USD | -4871095.652% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -2685.218% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -3329.317% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 97.992% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | -518.632% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 3.02 Million USD | -196.289% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 52.7 Million USD | 82.993% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | -865.881% |
| BioStem Technologies, Inc. | 14.56 Million USD | 38.442% |
| ONE Bio Corp. | 70.08 Million USD | 87.211% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -15598.672% |
| Burzynski Research Institute, Inc. | 2310.00 USD | -387908.658% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | -807.217% |
| Agentix Corp. | 261.39 Thousand USD | -3328.95% |
| LadRx Corporation | 2.3 Million USD | -288.365% |
| Cell Source, Inc. | 195.17 Thousand USD | -4492.383% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -1765.127% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -2434.663% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -2434.663% |
| NovAccess Global Inc. | 62.24 Thousand USD | -14298.856% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -1301.222% |
| Itoco Inc. | 1.4 Million USD | -540.181% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -9269.936% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -8355.66% |
| Kadimastem Ltd | 2.3 Million USD | -289.006% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -11638.743% |
| CytoDyn Inc. | 11.13 Million USD | 19.513% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -6169.06% |
| Mobile Lads Corp. | 52.00 USD | -17236438.462% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -50028.635% |
| Qrons Inc. | 420.00 USD | -2133947.619% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -2225.207% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -1523.379% |
| Rebus Holdings, Inc. | 5000.00 USD | -179160.0% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -2089.184% |
| International Stem Cell Corporation | 5.39 Million USD | -66.289% |
| Bioxytran, Inc. | 137.63 Thousand USD | -6412.01% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | 40.254% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | 45.938% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -11245.57% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | -936.572% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | -19.236% |
| Neutra Corp. | 2851.00 USD | -314280.919% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 72.342% |
| PureTech Health plc | 693.97 Million USD | 98.708% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | -11.051% |
| IXICO plc | 15.84 Million USD | 43.429% |
| IntelGenx Technologies Corp. | 8.28 Million USD | -8.223% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 91.325% |
| CSL Limited | 38.02 Billion USD | 99.976% |
| Cellectis S.A. | 333.99 Million USD | 97.316% |